| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eccd894c99fea2d1c0c8735872bb2309
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2013-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f4e22170b53b34561f19f40b758a56b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67b66dbeba92749e5368775037643613
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82261faf24e19f6ea9d268a401b7473e |
| publicationDate |
2015-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015265679-A1 |
| titleOfInvention |
Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor |
| abstract |
What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11786694-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10829518-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020123201-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11597749-B2 |
| priorityDate |
2012-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |